Industry top-down
Pharmaceutical Retailers
Latest reported revenue & EPS across the covered companies in this industry, with year-over-year (YoY) change. From disclosed earnings — not investment advice.
AI industry top-down
The pharmaceutical retail industry exhibited an overall slowdown in growth in the recent quarter, with its median revenue declining by 5.54% year-over-year. While some companies, such as PETS and Cellomax Science, experienced revenue declines, Polomar Health Services and Blue M Tech achieved high revenue growth of 54.56% and 28.85%, respectively, highlighting significant variations in company performance. Notably, despite its revenue decline, Cellomax Science's EPS increased by 64.06%.
- Sales of many companies decreased year-over-year.
- The median industry sales recorded negative growth.
AI synthesis of disclosed results and analyst research across these companies — not investment advice.
Companies — latest quarter
| Company | Period | Revenue | Rev YoY | EPS | EPS YoY | Surprise |
|---|---|---|---|---|---|---|
| BHICBioScience Health Innovations, Inc. | FY2026 Q1 | $1.23M | — | $0.01 | — | — |
| PETSPETMED EXPRESS INC | FY2026 Q3 | $176.21M | -17.9% | $0.26 | — | — |
| PMHSPolomar Health Services, Inc. | FY2025 Q3 | $37.95K | +54.6% | $-0.02 | — | — |
| DHTIDalrada Technology Group, Inc. | FY2026 Q3 | $13.72M | -5.5% | $-0.19 | — | — |
| 471820Cellromax Science Co., Ltd. | FY2026 Q1 | ₩4.71B | -20.4% | ₩105.00 | +64.1% | — |
| 439580BLUEMTEC CO., LTD. | FY2026 Q1 | ₩44.04B | +28.9% | ₩78.00 | — | — |
YoY = vs. the same quarter last year · Surprise = EPS actual vs. consensus. Latest reported quarter per company, from disclosed earnings filings. QoQ is omitted because quarterly filings don’t break out Q4 (US) and report cumulatively (KR).